Bayer's ESC 2026 Pipeline Showcase Collides With a Stinging Verdict on Capital Allocation

Bayer presents key cardio-renal data at ESC, but a new podcast highlights weak ROIC and high goodwill, keeping shares under pressure.

The late-August calendar is shaping up as a pivotal moment for Bayer's pharma narrative, even as a newly launched investor podcast casts a harsh light on the company's balance-sheet fundamentals. The Leverkusen-based group will present eleven data readouts at the European Society of Cardiology congress in Munich, scheduled for August 28–31, with fresh Phase-III evidence on two cardiovascular and renal assets taking center stage.

Kerendia, the company's finerenone product, will be the subject of new study data in chronic kidney disease. The drug has already secured US Food and Drug Administration approval for patients with chronic kidney disease alongside type 2 diabetes, as well as for heart failure with an ejection fraction of at least 40 percent. Alongside that, Bayer will unveil data on I-124-Evuzamitide, a diagnostic agent targeting cardiac amyloidosis — a rare but serious cardiac condition.

For shareholders, the cardiology conference carries weight beyond the scientific agenda. Kerendia ranks among the key growth drivers in Bayer's pharma division, which is tasked with offsetting the revenue erosion from the expiring Xarelto patent. Additional clinical evidence supporting expanded indications could underpin future sales contributions, though no immediate impact on the current fiscal year's numbers should be inferred from the presentations.

That pipeline optimism, however, is running headlong into a critical assessment from Warren Wise, whose newly launched podcast "Warrens Watchlist" puts both Bayer and SAP under the microscope. The central charge: despite a favorable US Supreme Court ruling in the glyphosate litigation, Bayer's return on invested capital has trailed its cost of capital for three consecutive years. By that measure, the company is theoretically destroying value rather than creating it. The analysis further flags that goodwill on the balance sheet exceeds shareholders' equity — a configuration widely viewed as a warning sign, reflecting how the multibillion-euro Monsanto acquisition continues to weigh on the company's financial structure.

The podcast's verdict places Bayer on the lowest rung of its five-tier rating framework, citing the combination of poor capital efficiency, elevated goodwill, and high overall indebtedness. The Supreme Court victory in the Roundup dispute is acknowledged as a positive, but the analysis contends that a single legal win does little to address structural issues that persist regardless of individual case outcomes.

The market's response has been muted at best. The stock closed at €48.44, down roughly 1.6 percent on the day, and traded around €48.35 on Thursday, a 1.7 percent decline that leaves the shares approximately ten percent below their 52-week high of €53.86, reached in early July. The pullback coincided with broader market weakness. Yet over a twelve-month horizon, the equity still shows a 74 percent gain — a rally that has tempered, without resolving, concerns about litigation exposure and capital efficiency.

Investors are thus left with a bifurcated picture. The clinical pipeline is generating substantive arguments for pharma growth ahead of the ESC gathering, while the structural balance-sheet questions Wise raises remain unanswered. The next opportunity for Bayer to counter the capital-efficiency critique arrives with third-quarter results, scheduled for November 3. Whether the Munich data can shift sentiment durably is a question that will only be answered after the congress concludes.